Introduction to Long-Acting Injectables

Innovative solutions for healthcare and patients

12

September

  • 3PM London / 10AM New York
  • Free

Why attend?

Long-acting injectables have emerged as a game-changing solution in the rapidly evolving world of healthcare. While patients around the globe are increasingly benefitting from the durable efficacy provided by these treatments, the development and in some cases adoption of these innovative treatments has been slow. Key challenges related to in some cases complex manufacturing, limited in vivo – in vitro correlation, and demanding regulatory and clinical framework have contributed to the relative rarity of long-acting products.  Long-acting injectables have improved the quality of life for patients. These innovative treatments have been proven to enhance effectiveness and improve patient compliance with dosing. As the demand for these advancements continues to grow, there has been a wide range of delivery technologies developed for various pharmaceutical products.

The webinar will focus on the landscape of long-acting injectables. We welcome three global experts in the field, Prof. René Holm of the University of Southern Denmark, Dr. Peter Markland of Tolmar Pharmaceuticals, and Dr. Mika Jokinen of DelSiTech to provide their unique perspectives on the long-acting injectable technology space as it stands today. Dr. René Holm will lead us through the long-acting injectables landscape enabling more effective treatment. Dr. Peter Markland from Tolmar will express the benefits of long-acting injectables in treating various diseases. Dr. Mika Jokinen from DelSiTech will present Silica Matrix technology as a sustained delivery from subcutaneous to intravitreal administration routes.

Learning objective:

  • Long acting injectables
  • Parenteral drug delivery
  • Silica Matrix technology
  • Ophthalmology

Speakers

Select a speaker to learn more

Back
Frederic Dargelas
Director, Head of Business Development and Alliance Management

Dr. Frederic Dargelas is the Director, Head of Business Development and Alliance Management of DelSiTech. He joined the company in 2019. Dr. Dargelas is a business development and R&D veteran with almost 20 years of experience in the pharma and biotech industry. Previously, he held managing positions at diverse international companies such as GSK and Orion Pharma. Dr. Dargelas holds a PhD in Physical Chemistry of Polymers and an MBA.

Next speaker
Back
René Holm
Professor in Pharmaceutical physical chemistry

Dr. René Holm is a professor in pharmaceutical physical chemistry at the University of Southern Denmark. After receiving Master and PhD degree in pharmaceutics from the University of Copenhagen, Denmark, in 2002, he started his carrier in the pharmaceutical industry at H.Lundbeck in 2001 and changed to Janssen in 2016. Dr. Holm has worked within pharmaceutical development, formulations for non-clinical testing in drug discovery, physical chemistry and material science covering both small and large molecules. In 2021 Dr. Holm engaged into a carrier change and became a full professor. Dr. Holm is (co-) author of more than 240 original articles in peer-reviewed journals and book chapters in the field of biopharmaceutics, preformulation, formulation and physical pharmacy and book chapters and is co-inventor on 19 published patents.

Next speaker
Back
Peter Markland
Senior Research Fellow, New Product Development

Dr. Peter Markland is a Pharmaceutical scientist with over 20 years of experience in drug delivery research, technology, and biomaterials development. His expertise includes directing internal drug delivery research and product development teams, and evaluating external delivery technologies. Dr Markland has also been involved in program management and marketing for novel, controlled release dosage forms and have experience in formulation development of a wide variety of drugs for various routes of administration.

Next speaker
Back
Mika Jokinen
Chief Scientific Officer

Dr. Jokinen is a co-founder of DelSiTech and Chief Scientific Officer of in the company. In addition, he is a Principal Lecturer in chemical and biochemical engineering at the Turku University of Applied Sciences. He has over 20 years R&D experience in silica-based biomaterials. Dr. Jokinen holds a Doctor of Science in Technology and has a position as Adjunct Professor in Medical Biomaterials at Åbo Akademi University, Turku, Finland.

Next speaker
Back
Lasse Leino
PhD, Chief Executive Officer

Dr. Leino is the company’s President and Chief Executive Officer and has more than 20 years life science business experience. He is the founder and former President and CEO of BioCis Pharma Ltd as well as the first CEO and COO of Laurantis Pharma Ltd. Previously, Dr. Leino has worked in various R&D management positions in Orion Pharma, BioTie Therapies Ltd, and AstraZeneca in Lund, Sweden. Dr. Leino holds a PhD in biochemistry and has a position as Adjunct Professor in immunology at the University of Turku, Finland.

Next speaker

Enquiry